Cardiff Oncology initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Cardiff Oncology (CRDF) with a Buy rating and $14 price target Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel oncology therapies, the analyst tells investors in a research note. The firm believes the company’s lead asset, onvansertib, will be a “significant value driver” for shares as the asset is “de-risked” with positive clinical data metastatic colorectal cancer.